The value of AFP combined with AFP-L3, GPC3 and MMP2 detection in the diagnosis of hepatocellular carcinoma

doi:10.19871/j.cnki.xfcrbzz.2022.04.008

Abstract

Abstract: Objective The purpose of detecting the expression of serum AFP,AFP-L3, GPC3 and MMP2 was to study the diagnostic value of the combined detection of four indicators in HCC．Method 60 HCC patients,60 case of liver cirrhosis patients,60 cases of chronic viral hepatitis B ( HBV) patients and 60 healthy controls were selected from Outpatients in Public Health Clinical Center of Chengdu from December 2019 to December 2020.The serum AFP,AFP-L3 and GPC3,MMP2 detected with chemiluminescence and enzyme-linked immunosorbent double antibody sandwich method, respectively. Analyzed the differences of serum marker in each group, and the diagnostic efficiency of combined detection was calculated. Result The levels of serum AFP,AFP-L3,GPC3,and MMP2 in HCC patients were significantly higher than those of other non-HCC groups,and the differences were statistical significance(M =122.3 μg/L, 88.33 μg/L, 53.45 pg/ml, 701.3 μg/L;H =125.8, 167.5, 209.4, 210.4; P< 0.05). The diagnostic accuracy of the combined detection of four indicators was 89.3%, the sensitivity and specificity were 84.87% and 84.59%, respectively, and the area under the curve was 0.905, which was higher than that of single detection, there are significant difference in those three groups(P< 0.05). Conclusion The combined detection of serum AFP, AFP-L3, GPC3 and MMP2 are the risk factors of HCC ppatients, which is helpful to the early diagnosis and treatment of cancer in high-risk patients with hepatocellular carcinoma, and improve survival time of patients and the survival rate.

Key words: Alpha fetoprotein, Alpha fetoprotein variants-L3, Glypican 3, Matrix metalloproteinase 2, Hepatocellular carcinoma

Pang Wenxiao, Li Jike, Chen Tingyu, Zhao Yong, Wei Guo. The value of AFP combined with AFP-L3, GPC3 and MMP2 detection in the diagnosis of hepatocellular carcinoma[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(4): 33-36.

References

[1] WONG M CS, JIANG JY, GOGGINS WB, et al.International incidence and mortality trends of liver cancer: a global profile[J]. Sci Rep, 2017, 7(1):846-855.
[2] YARCHOAN M, AGARWAL P, VLLANUEVAL A, et al.Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma[J]. Cancer Res, 2019, 79(17):4326-4330.
[3] SCHEAU C, BADARAU IA, CARUNTU C, et al.Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma[J]. Molecules, 2019, 24(13):350-366.
[4] ZONG J, FAN Z, ZHANG Y.Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma[J]. J Hepatocell Carcinoma, 2020, 7:413-422.
[5] 高娟, 李盼盼. AFP、AFP-L3%与GP73联合检测对原发性肝癌的诊断价值[J]. 数理医药学杂志, 2022, 35(1):112-114.
[6] LONGERICH T.Hepatocellular carcinoma[J]. Der Pathologe, 2020, 41(5):478-487.
[7] CHEN L, YI X, GUO P, et al.The role of bone marrow-derived cells in the origin of liver cancer revealed by single-cell sequencing[J]. Cancer Biol Med, 2020, 17(1):142-153.
[8] TANG W, CHEN Z, ZHANG W, et al.The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects[J]. Signal Transduct Target Ther, 2020, 5(1):87-102.
[9] HUANG A, YANG XR, CHUNG WY, et al.Targeted therapy for hepatocellular carcinoma[J]. Signal Transduct Target Ther, 2020, 5(1):146-159.
[10] MEJIA JC, PASKO J.Primary Liver Cancers[J]. Surg Clin North Am, 2020, 100(3):535-549.
[11] LIU W, ZHANG F, QUAN B, et al.The Prognostic Value of the Albumin to Gamma-Glutamyltransferase Ratio in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation[J]. Dis Markers, 2021, 2021:1-10.
[12] ASSALINO M, TERRAZ S, GRAT M, et al.Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi‐center retrospective cohort study[J]. Trans Inter, 2020, 33(5):567-575.
[13] MAZZOTTA AD, PASCOLE A, CANO L, et al.Number of hepatocellular carcinoma nodules in patients listed for liver transplantation within alpha‐fetoprotein score: a new prognostic risk factor[J]. Trans Inter, 2021, 34(5):954-963.
[14] XU W, ZHANG Z, ZHANG Y, et al.alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma[J]. Onco Targets Ther, 2015, 9:123-129.
[15] ZHOU JM, WANG T, ZHANG KH.AFP-L3 for the diagnosis of early hepatocellular carcinoma[J]. Med, 2021, 100(43):e27673.
[16] CHEN S, LI J, TAN X, et al.Clinical role of combining alpha‐fetoprotein and lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein for hepatocellular carcinoma: Evidence from literature and an original study[J]. J Clin Lab Anal, 2020, 34(7):e23262.
[17] KAMIMURA K, MAEDA N.Glypicans and Heparan Sulfate in Synaptic Development, Neural Plasticity, and Neurological Disorders[J]. Front Neural Circuits 2021, 15(10):596-613.
[18] FILMUS J, CAPURRO M, RAST J.Glypicans[J]. Genome Biol, 2008, 9(5):224-230.
[19] NASHIDA T, KATAOKA H.Glypican 3-Targeted Therapy in Hepatocellular Carcinoma[J]. Cancers 2019, 11(9):13-39.
[20] TSUCHIYA N.Biomarkers for the early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(37):573-583.
[21] FU Y, URBAN DJ, NANI RR, et al.Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma[J]. Hepatology, 2019, 70(2):563-576.
[22] SUN L, GAO F, Gao Z, et al.Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma[J]. J Immunother Cancer, 2021, 9(4):e001875.
[23] ZHANG L, LIU H, SUN L, et al.Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: A tissue microarray-based study[J]. Acta Histochem, 2012, 114(6):547-552.
[24] CUI N, HU M, Khalil RA.Biochemical and Biological Attributes of Matrix Metalloproteinases[J]. Prog Mol Biol Transl Sci, 2017, 147:1-73.
[25] PASTUSHANKU I, MAURI F, SONG Y, et al.Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis[J]. Nature, 2020, 589(7842):448-455.
[26] WANG BIN, DING YM, Fan P, et al.Expression and significance of MMP2 and HIF-1α in hepatocellular carcinoma[J]. Onco Lett, 2014, 8(2):539-546.
[27] SCHOEDEL KE, TYNER VZ, KIM TH, et al.HGF, MET, and Matrix-Related Proteases in Hepatocellular Carcinoma, Fibrolamellar Variant, Cirrhotic and Normal Liver[J]. Mod Pathol, 2003, 16(1):14-21.